Encompass Health (EHC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
The annual meeting will be held virtually on May 7, 2026, with voting available online, by phone, mail, or during the meeting for shareholders of record as of March 9, 2026.
Shareholders will vote on the election of 10 directors, ratification of the independent auditor, and an advisory say-on-pay vote for executive compensation.
The board and all committees are majority independent, with robust governance practices, annual evaluations, and active shareholder engagement.
Voting matters and shareholder proposals
Shareholders will elect 10 directors to serve until the 2027 annual meeting.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 is recommended.
Advisory approval of executive compensation is sought, with the board recommending a vote in favor.
Shareholders may submit proposals for the 2027 meeting between January 7 and February 6, 2027.
Board of directors and corporate governance
9 of 10 directors are independent; the board is declassified with annual elections.
Board committees (Audit, Compensation and Human Capital, Compliance and Quality of Care, Nominating/Corporate Governance) are fully independent.
Diversity is emphasized: three directors are female and three identify as members of underrepresented groups.
Directors are subject to term limits and a mandatory retirement age, with exceptions at the board's discretion.
Stockholders representing 20% of shares may call a special meeting; written consent is permitted.
Latest events from Encompass Health
- Expansion, innovation, and disciplined capital use drive positive outlook and operational momentum.EHC
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Double-digit growth in revenue, EBITDA, and EPS in 2025, with strong 2026 outlook.EHC
Q4 20256 Feb 2026 - Double-digit revenue and earnings growth in Q1 led to higher full-year guidance.EHC
Q1 20253 Feb 2026 - Q2 2024 revenue rose 9.6% and net income 24.8%, prompting higher full-year guidance.EHC
Q2 20242 Feb 2026 - Q3 2024 saw 11.9% revenue growth, higher earnings, and a raised full-year outlook.EHC
Q3 202418 Jan 2026 - Q4 2024 saw strong growth in revenue, earnings, and cash flow, with a positive 2025 outlook.EHC
Q4 20248 Jan 2026 - All voting items passed with strong support and no stockholder questions were raised.EHC
AGM 202524 Dec 2025 - Sustained growth, clinical excellence, and capital discipline drive expansion and strong returns.EHC
Barclays 27th Annual Global Healthcare Conference20 Dec 2025 - 2025 meeting features key votes on directors, pay, auditor, and a new performance incentive plan.EHC
Proxy Filing1 Dec 2025